Teva Pharmaceutical Industries recently reported FDA approval of PONLIMSI (denosumab-adet) as a Prolia biosimilar for all reference indications, alongside FDA and EMA acceptance of its proposed Xolair ...
Zacks Investment Research on MSN
Teva's Prolia biosimilar gets FDA nod, Xolair filing accepted
Teva Pharmaceutical Industries Ltd. TEVA announced that the FDA has approved its biosimilar to Amgen’s AMGN blockbuster drug, ...
Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...
Pharmaceutical Technology on MSN
Teva receives FDA approval for Prolia biosimilar
The FDA approval for Ponlimsi is based on comprehensive evidence, including analytical and clinical data.
Add Yahoo as a preferred source to see more of our stories on Google. The FDA has introduced a new draft guidance The US Food and Drug Administration (FDA) has debuted new draft guidance that aims to ...
The Food and Drug Administration has approved Teva's Prolia biosimilar and the agency is reviewing Teva's Xolair biosimilar application.
On March 30, 2026, the FDA approved Ponlimsi, a biosimilar to Prolia, and is reviewing a biosimilar candidate for Xolair.
Biologic copycats are making a bigger impact on drug prices as U.S. regulators open the doors wider, and new guidance could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results